Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Ladenburg Thalmann Downgrades Calithera Biosciences to Neutral

Ladenburg Thalmann analyst Aydin Huseynov downgrades Calithera Biosciences (NASDAQ:CALA) from Buy to Neutral.
byBenzinga Newsdesk
November 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Ladenburg Thalmann analyst Aydin Huseynov downgrades Calithera Biosciences (NASDAQ:CALA) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

IPO Previews For The Week

By Benzinga Insights
March 31, 5:43 PM
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

MNDR

Read More

Nasdaq, S&P 500 Futures Keep Head Above Water Ahead Of Fed Speeches: Analyst Says Market-Boosting Themes ‘Firmly In Place’

By Shanthi Rexaline
May 20, 7:48 AM
U.S. index futures are modestly higher in early trading on Monday, suggesting that the upward momentum remains intact, albeit laced with caution. Traders will likely scan speeches by Federal Reserve officials for confirmation regarding rate trajectory. The global markets have taken development in the Middle East in their stride, underlining their resilience.

BTC